Niacinamide for Health & Longevity

Evidence Review created on 11/21/2026 using AI4L + evidence-mcp / Opus 5.5

Also known as: Nicotinamide, Nicotinic Acid Amide, Pyridine-3-carboxamide, NAM, Vitamin B3

Motivation

Niacinamide, also called nicotinamide, is a form of vitamin B3. It occurs in meat, fish and fortified grains, is sold as an inexpensive supplement, and is a common skin-cream ingredient. The body uses it to rebuild a helper molecule that every cell needs to produce energy and repair its genetic material, and levels of that molecule fall with age.

Interest grew when Australian dermatologists tested high oral doses in people with heavily sun-damaged skin to see whether it could prevent new skin cancers, and when eye researchers tested it to protect the nerve cells lost in glaucoma. It also sits at the center of the debate over vitamin B3 forms marketed for healthy aging, where some researchers see it as the least expensive source of that helper molecule and others as a possible brake on the repair enzymes it is meant to support.

This review examines the human evidence on oral and topical niacinamide for health and longevity, focusing on skin cancer, eye health and safety at the gram-level doses used in trials.

Benefits - Risks - Protocol - Conclusion

Expert content on niacinamide’s skin effects, its role as a precursor of NAD+ (nicotinamide adenine dinucleotide, the coenzyme every cell uses for energy production and DNA repair), and its safety.

  • How to Improve Skin Health & Appearance - Andrew Huberman

    Reviews oral and topical niacinamide for skin aging and sun damage alongside sunscreen, retinoids (vitamin A-derived skin drugs) and collagen, and links studies on nicotinamide’s protection against UV (ultraviolet) energy loss and DNA damage.

  • Sun Protection from the Inside Out - Sarah LoBisco

    Summarizes human data on oral nicotinamide for UV-induced skin immune suppression and new skin cancers in high-risk people. Life Extension sells nicotinamide supplements, a commercial interest in the topic.

  • #27 - David Sinclair, Ph.D.: Slowing aging – sirtuins, NAD, and the epigenetics of aging - Peter Attia

    Contains a segment on nicotinamide as an inhibitor of sirtuins (NAD+-dependent enzymes that regulate gene activity and stress responses), the core tension in its longevity use. Sinclair co-founded companies developing NAD+ precursors.

  • NAD+ in Aging: Role of Nicotinamide Riboside and Nicotinamide Mononucleotide - Rhonda Patrick

    Explains the NAD+ salvage (recycling) pathway that nicotinamide feeds, and notes that oral NR (nicotinamide riboside) and NMN (nicotinamide mononucleotide) are largely converted to nicotinamide before reaching most tissues.

  • Niacin (Vitamin B3) Linked to Cardiovascular Risk - Arkadi Mazin

    Covers the finding linking 2PY and 4PY (terminal breakdown products shared by nicotinamide and niacin) to major cardiovascular events, a key open safety question for high-dose vitamin B3.

No item from Chris Kresser is listed: chriskresser.com was searched, and its niacin articles discuss nicotinic acid and skin nutrition without substantive nicotinamide content.

Grokipedia

Nicotinamide

AI-generated encyclopedia overview of nicotinamide chemistry, pellagra (niacin deficiency) treatment, dermatologic uses and the 500 mg twice-daily skin cancer regimen; useful for orientation, but its claims need checking against primary studies.

Examine

Nicotinamide benefits, dosage, and side effects

Independent summary of studied oral doses (25 mg to 6 g daily, for up to 5 years) and topical concentrations (1–5%), with graded human outcomes; the detailed effect ratings require a subscription.

ConsumerLab

B Vitamin Supplements Review (B Complexes, B6, B12, Biotin, Folate, Niacin, Riboflavin & More)

Independent laboratory testing of B vitamin products for label accuracy, with a members-only niacin section covering niacinamide for skin cancer and glaucoma.

Systematic Reviews

Five systematic reviews and meta-analyses covering skin cancer prevention, glaucoma, phosphate control in dialysis and adverse effects.

Mechanism of Action

Niacinamide is mainly raw material for NAD+. In the salvage pathway, NAMPT (nicotinamide phosphoribosyltransferase, the rate-limiting enzyme of NAD+ recycling) turns nicotinamide into NMN, which becomes NAD+. Enzymes that consume NAD+, chiefly PARPs (poly(ADP-ribose) polymerases, DNA-repair enzymes) and sirtuins, release nicotinamide again; in cell lines, NAD+ was made from nicotinamide and consumed largely by PARPs and sirtuins (Liu 2018).

  • Skin: In keratinocytes (the main cells of the outer skin) and in human skin exposed to UV light, nicotinamide enhanced repair of two kinds of UV-induced DNA damage (Surjana 2013).
  • Competing view: Nicotinamide also feeds back to inhibit sirtuins. In mice, long-term supplementation did not raise liver NAD+ and increased acetylation (chemical tagging that alters protein activity) of some SIRT1 (sirtuin 1) targets (Mitchell 2018); whether supplemental doses support or restrain these enzymes is unresolved.
  • Pharmacokinetics (how the body absorbs and clears it): Half-life is dose-dependent: about 1.5 hours after 1 g (Stratford 1992), 4 hours after 2 g (Stratford 1992) and 7–9 hours after 4–6 g (Stratford 1992). It acts on no single receptor and distributes widely, but spinal-fluid nicotinamide was measurable in only 6 of 19 treated participants in one trial (Ketron 2025).
  • Metabolism: NNMT (nicotinamide N-methyltransferase, a liver enzyme that attaches a methyl group) converts it to methylnicotinamide, which aldehyde oxidase (a liver enzyme) converts to a breakdown product excreted in urine (Fashe 2024). In patients, it slowed carbamazepine and primidone metabolism, probably by inhibiting CYP450 (cytochrome P450, the main drug-metabolizing liver enzymes) (Bourgeois 1982).

Historical Context & Evolution

Nicotinamide was identified in the late 1930s as a cure for pellagra (a niacin-deficiency disease of dermatitis, diarrhea and dementia). The amide form became preferred for supplements and food fortification because, unlike nicotinic acid, it does not cause flushing.

From the 1980s, high doses were tested to protect insulin-producing cells. A meta-analysis of early trials found higher residual insulin output one year after type 1 diabetes diagnosis (Pozzilli 1996), but the 552-person ENDIT trial found no prevention of type 1 diabetes in at-risk relatives (Gale 2004). According to a safety review, doses up to 6 g/day were also combined with radiotherapy to sensitize tumors (Knip 2000).

A Sydney research group led by Diona Damian then studied nicotinamide against UV damage. Its phase 3 trial reported fewer new skin cancers in high-risk adults (Chen 2015); its later trial in organ transplant recipients found no benefit (Allen 2023). In 2017, oral nicotinamide prevented glaucoma in most eyes of aged glaucoma-prone mice (Williams 2017), launching human glaucoma trials.

The NAD+ aging hypothesis then drew nicotinamide into longevity discussions, although mice gained health measures without longer life (Mitchell 2018), and 2024 metabolite data raised cardiovascular questions (Ferrell 2024). The pattern so far is strong animal signals with mixed human translation; large glaucoma and transplant trials now under way will shape its standing.

Expected Benefits

High 🟩 🟩 🟩

Improved Appearance of Sun-Aged Facial Skin (Topical) ⭕️ Not Central to Health & Longevity

Applied as a 5% cream twice daily for 12 weeks, niacinamide reduced fine lines and wrinkles, hyperpigmented spots, red blotchiness and yellowing, and improved elasticity versus its vehicle (base cream) in a split-face (one side treated, the other as control) randomized trial of 50 women (Bissett 2005). Bissett’s group worked for Procter & Gamble, a niacinamide skin-care seller. A Japanese university group led by Kawada found less eye-area wrinkling with a 4% niacinamide cosmetic from Procter & Gamble Japan (Kawada 2008). This bears on skin appearance, not health or lifespan.

Magnitude: In the Kawada split-face trial, marked or moderate wrinkle improvement occurred in 64% of 30 women on the 4% niacinamide side versus 0% on the control side after 8 weeks (P < 0.001; P, the probability of a difference this large arising by chance alone) (Kawada 2008).

Medium 🟩 🟩

Fewer Keratinocyte Cancers and Actinic Keratoses After Prior Skin Cancer ⚠️ Conflicted

In immunocompetent adults with two or more prior keratinocyte cancers (basal-cell or squamous-cell carcinomas), 500 mg twice daily for 12 months reduced new cancers and actinic keratoses (scaly precancerous sun-damage patches), without benefit after stopping (Chen 2015). In a VA (Veterans Affairs) cohort of 33,822 patients, use was linked to 14% lower skin cancer risk (Breglio 2025). The same group’s transplant trial found no effect (Allen 2023); a meta-analysis pooling both populations found no significant reduction (Tosti 2023). Net: a modest benefit in immunocompetent high-risk adults, lasting only while taken.

Magnitude: New keratinocyte cancers 23% lower than placebo at 12 months (1.8 versus 2.4 per person, 336 versus 463 cancers; 95% CI 4 to 38; CI, confidence interval, the range likely to contain the true effect) (Chen 2015); in transplant recipients, 207 versus 210 new cancers, rate ratio (ratio of event rates between groups) 1.0 (95% CI 0.8 to 1.3) (Allen 2023).

Lower Serum Phosphate in Dialysis ⚠️ Conflicted ⭕️ Not Central to Health & Longevity

In hemodialysis patients, a meta-analysis of 9 RCTs with 428 patients found lower serum phosphorus and parathyroid hormone with nicotinamide than with control (Zhang 2018). In the largest trial, NOPHOS (funded by the manufacturer MEDICE), add-on modified-release nicotinamide lowered phosphate at week 24 but not at week 52 (Ketteler 2023). This bears on mineral control in kidney failure, not on aging in healthy adults. Net: a short-term phosphate-lowering effect that did not persist in the largest trial.

Magnitude: Serum phosphorus SMD (standardized mean difference, the effect in standard-deviation units) −1.06 versus control (95% CI −1.27 to −0.85) (Zhang 2018); in NOPHOS, a mean difference of −0.39 mg/dL versus placebo at week 24 (95% CI −0.66 to −0.13) (Ketteler 2023) and −0.08 mg/dL at week 52 (95% CI −0.36 to 0.20) (Ketteler 2023).

Preserved Insulin Output After Type 1 Diabetes Diagnosis ⚠️ Conflicted ⭕️ Not Central to Health & Longevity

A meta-analysis of 10 randomized trials, 5 of them placebo-controlled, found higher C-peptide (the body’s own insulin output) a year after type 1 diabetes diagnosis with add-on nicotinamide, without lower HbA1c (3-month average glucose) (Pozzilli 1996). The 56-patient IMDIAB III trial found no overall difference (Pozzilli 1995). This bears on autoimmune diabetes, not aging. Net: the pooled trials favor preserved insulin output, which the smaller single trial did not confirm.

Magnitude: C-peptide 0.73 versus 0.32 ng/mL in controls one year after diagnosis (Pozzilli 1996).

Low 🟩

Treatment and Prevention of Pellagra (Niacin Deficiency)

Pellagra, the niacin-deficiency disease of dermatitis, diarrhea and dementia, is treated by giving niacinamide, according to a review of its clinical management (Hołubiec 2021). Untreated, it can be fatal. The evidence is clinical experience and case reports, not controlled trials; deficiency is rare in well-nourished adults.

Magnitude: Not quantified in available studies. Pellagra treatment rests on historical clinical experience and case reports, and no controlled trial has measured response rates.

Better Inner-Retinal Function in Glaucoma ⚠️ Conflicted

Two independent crossover RCTs (each patient took both treatments) found improved photopic negative response (an electrical retinal recording of optic-nerve cell function) (Hui 2020; Ha 2026). Visual field outcomes did not differ between groups in one trial (Ha 2026). Net: electrical improvement without shown protection of vision.

Magnitude: Photopic negative response amplitude rose 14.8% on nicotinamide (95% CI 2.8 to 26.9) and 5.2% on placebo (95% CI −4.2 to 14.6), not compared between groups (Hui 2020); peak-to-trough amplitude rose 3.12 μV on nicotinamide versus 1.00 μV on placebo (p = 0.045) (Ha 2026).

Type 1 Diabetes Prevention in At-Risk People ⚠️ Conflicted ⭕️ Not Central to Health & Longevity

A New Zealand study led by Elliott reported lower type 1 diabetes incidence in schoolchildren screened and treated with nicotinamide (Elliott 1996). In 552 at-risk relatives, the randomized ENDIT trial found no prevention (Gale 2004). Bears on autoimmune diabetes, not aging. Net: the stronger randomized evidence shows no prevention.

Magnitude: Diabetes onset in 82 versus 77 participants, HR (hazard ratio, the relative event rate over time) 1.07 versus placebo (95% CI 0.78 to 1.45) (Gale 2004).

Slower Clinical Decline in Early Alzheimer Disease ⚠️ Conflicted

In a 47-person phase 2a trial, 3 g/day for 48 weeks did not lower spinal-fluid p-tau231 (a marker of tau-tangle pathology), the primary endpoint (Grill 2025). A dementia-severity score declined less, unadjusted for the many outcomes tested, while cognitive scores did not differ (Grill 2025). Net: no reliable benefit.

Magnitude: CDR-SB (Clinical Dementia Rating Sum of Boxes, a dementia-severity scale) worsened 1.42 points less than with placebo at 48 weeks (SE, standard error, 0.65; unadjusted p = 0.03) (Grill 2025); ADAS-cog (Alzheimer’s Disease Assessment Scale, cognitive subscale) difference 1.93 points (SE 1.93; p = 0.32) (Grill 2025).

Speculative 🟨

Healthspan Extension Through NAD+ Repletion

In mice on a high-fat diet, long-term nicotinamide improved glucose handling and fatty liver but did not extend lifespan or raise liver NAD+ (Mitchell 2018). No human aging-outcome data exist; the basis is animal only.

Benefit-Modifying Factors

  • Genetic polymorphisms: No variant has been tested for benefit. NNMT activity varies between people, and in an Alzheimer trial most treated participants inactivated nicotinamide to methylnicotinamide rather than raising spinal-fluid levels (Ketron 2025).
  • Baseline biomarkers and history: Skin cancer risk reduction was largest when nicotinamide started after a first skin cancer and smaller after later cancers (Breglio 2025). Serum nicotinamide is low in glaucoma patients (Kouassi Nzoughet 2019), but no trial tested whether baseline levels predict response.
  • Sex: No sex-specific benefit analyses exist. Skin cancer cohort data are almost entirely from men (2% women) (Breglio 2025), and the topical skin trial enrolled only women (Bissett 2005).
  • Pre-existing conditions: Immunosuppression after organ transplant removed the skin cancer benefit in a randomized trial (Allen 2023). Kidney failure defines the only setting with phosphate-lowering data.
  • Age: Benefit data come from older adults: mean age 77 in the VA cohort (Breglio 2025) and 74 in the Alzheimer trial (Grill 2025). No trial tested younger adults for prevention.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Gastrointestinal Upset and Diarrhea ⚠️ Conflicted

Digestive adverse effects increased with nicotinamide across randomized trials in a meta-analysis by Mainville (Mainville 2022), and diarrhea increased in the NOPHOS dialysis trial led by Ketteler (Ketteler 2023). In a kidney-transplant pilot, 1,000 mg twice daily had to be reduced to 500 mg twice daily because of gastrointestinal symptoms (Zhang 2023). In contrast, the 386-person skin cancer trial at 500 mg twice daily found no noteworthy between-group differences in adverse events (Chen 2015). Net: digestive effects are real, mostly mild, and commoner at gram doses and in kidney disease.

Magnitude: Digestive adverse effects RR (relative risk) 1.78 versus control (95% CI 1.30 to 2.45), with per-group rates not reported in the source (Mainville 2022); diarrhea in 44.4% versus 27.9% on placebo, HR 2.13 (95% CI 1.66 to 2.74) (Ketteler 2023).

Thrombocytopenia in Kidney Failure

In people on hemodialysis, nicotinamide lowered platelet counts in an Iranian trial led by Shahbazian at 500–1,000 mg/day (Shahbazian 2011) and in the international NOPHOS trial led by Ketteler (Ketteler 2023). A meta-analysis of hemodialysis trials confirmed a higher thrombocytopenia risk without serious adverse reactions (Zhang 2018). The mechanism is unknown; reduced kidney clearance raises exposure. Low platelets increase bleeding tendency.

Magnitude: Thrombocytopenia in 5.2% versus 1.1% on placebo, HR 6.39 (95% CI 1.54 to 26.52) (Ketteler 2023); pooled RR 2.82 versus control (95% CI 1.14 to 6.94), with pooled per-group rates not reported in the source (Zhang 2018).

Medium 🟥 🟥

Pruritus in Dialysis

In NOPHOS, 722 hemodialysis patients took modified-release nicotinamide (250–1,500 mg/day) or placebo on top of phosphate binders (drugs that bind dietary phosphate in the gut) (Ketteler 2023). Nicotinamide raised the risk of pruritus (itching) (Ketteler 2023). The signal comes from one manufacturer-funded trial in kidney failure, and its mechanism is unknown.

Magnitude: Pruritus in 13.7% versus 6.6% on placebo, HR 2.76 (95% CI 1.52 to 5.03) (Ketteler 2023).

Anemia in Dialysis

In the NOPHOS hemodialysis trial, nicotinamide raised the risk of anemia compared with placebo (Ketteler 2023). The signal comes from one manufacturer-funded trial in kidney failure, where anemia is already common, and its mechanism is unknown.

Magnitude: Anemia in 11.1% versus 7.1% on placebo, HR 2.17 (95% CI 1.23 to 3.81) (Ketteler 2023).

Herpes Zoster in Dialysis

In the NOPHOS hemodialysis trial, all herpes zoster (shingles) cases occurred in the nicotinamide group (Ketteler 2023). The signal comes from one manufacturer-funded trial in kidney failure, and its mechanism is unknown.

Magnitude: Herpes zoster in 5.4% versus 0% on placebo (Ketteler 2023).

Low 🟥

Liver Injury at Multi-Gram Doses

A safety review found infrequent minor liver-enzyme rises at diabetes-prevention doses and reversible hepatotoxicity (liver toxicity) at very high doses, including a case at 9 g/day confirmed by rechallenge (recurrence on re-exposure) (Knip 2000). It classed adult doses above 3 g/day as having toxic potential (Knip 2000).

Magnitude: Not quantified in available studies. The evidence is a single rechallenge-confirmed case report and uncontrolled enzyme observations, and no trial reports an incidence.

Reduced Insulin Sensitivity

In 8 antibody-positive (carrying immune markers of diabetes risk) relatives of people with type 1 diabetes, 2 g/day for 2 weeks lowered insulin sensitivity despite higher insulin secretion (Greenbaum 1996). The study was short and uncontrolled. Clinical relevance at lower doses is unknown.

Magnitude: Insulin sensitivity fell 23.6% after 2 weeks, no control group (Greenbaum 1996).

Cardiovascular Events via 4PY Metabolite ⚠️ Conflicted

Higher blood 2PY and 4PY (end products of vitamin B3) predicted MACE (major adverse cardiovascular events) in two cohorts (Ferrell 2024), and 4PY promoted vascular inflammation in mice (Ferrell 2024). Indirect: metabolite levels, not intake. Nicotinamide users showed no MACE excess in two cohorts (Wheless 2025). Net: an unconfirmed concern.

Magnitude: 4PY HR 1.89 (95% CI 1.26 to 2.84) in the US validation cohort (Ferrell 2024); MACE HR 0.76 (95% CI 0.46 to 1.25) in nicotinamide users versus non-users in one cohort (Wheless 2025) and 1.00 (95% CI 0.75 to 1.32) in the other (Wheless 2025).

Speculative 🟨

Sirtuin Inhibition Opposing Longevity Pathways

Nicotinamide feeds back to inhibit sirtuins; in mice it increased acetylation of some SIRT1 targets (Mitchell 2018). Whether supplemental doses blunt human sirtuin activity is unknown; the basis is mechanistic only.

Methyl-Group Drain

Clearing nicotinamide consumes methyl groups: methylnicotinamide rose over 600-fold on 3 g/day (Ketron 2025), and 300 mg raised homocysteine (a methyl-shortage marker) 61% versus water at 3 hours (Sun 2017). Clinical effects are untested.

Risk-Modifying Factors

  • Genetic polymorphisms: The variant rs10496731 in ACMSD (a gene for an enzyme that regulates NAD+ synthesis from tryptophan) is associated with blood 2PY and 4PY levels (Ferrell 2024). Differences in NNMT and aldehyde oxidase activity may change metabolite exposure; no genotype-guided dosing exists.
  • Baseline biomarkers: A low platelet count, raised liver enzymes or impaired glucose tolerance leaves less margin for the platelet, liver and insulin-sensitivity effects above.
  • Sex and pregnancy: No sex difference in adverse effects is reported. Pregnancy did not change nicotinamide exposure after 1 g (Fashe 2024), but the EU upper level, restated in a European Food Safety Authority novel-food opinion, excludes pregnancy and lactation (no data) (EFSA opinion).
  • Pre-existing conditions: An overview of reviews found adverse effects more common at higher doses and limiting tolerability in renal dysfunction (Young 2025). Liver disease, epilepsy treated with carbamazepine or primidone, and diabetes add specific risks.
  • Age: Older adults, the main users for skin cancer and glaucoma, more often have reduced kidney function and several medications; the VA cohort averaged 77 years (Breglio 2025).

Key Interactions & Contraindications

Documented interactions:

  • Carbamazepine: Nicotinamide raised carbamazepine levels in two patients, probably by inhibiting CYP450 (Bourgeois 1982). Consequence: carbamazepine toxicity (dizziness, unsteadiness, double vision). Mitigation: carbamazepine level checks after starting or changing nicotinamide.
  • Primidone: Nicotinamide reduced conversion of primidone to phenobarbital in patients, in proportion to its dose (Bourgeois 1982). Consequence: altered seizure control or sedation. Mitigation: primidone and phenobarbital level checks.
  • Omeprazole (acid-reducing drugs): Omeprazole pretreatment did not change nicotinamide absorption or peak levels in volunteers (Stratford 1996); no interaction found. Consequence: none expected; no timing separation needed.
  • Phosphate binders (sevelamer, calcium acetate, lanthanum carbonate): As add-on therapy in hemodialysis, nicotinamide lowered phosphate further for 24 weeks but added thrombocytopenia, diarrhea, itching and anemia (Ketteler 2023). Mitigation: nephrologist supervision with platelet monitoring.
  • Radiotherapy: Nicotinamide has been combined with radiotherapy and carbogen breathing (a high-oxygen gas mixture) to sensitize tumors, and a safety review reports nausea at 6 g/day in that setting (Knip 2000). Consequence: altered radiation response and nausea. Mitigation: disclosure of use to the radiation oncologist.

Theoretical interactions (inferred from mechanism, not studied in humans):

  • Other vitamin B3 forms (nicotinic acid, NR, NMN): Inferred from shared NNMT methylation and 2PY/4PY formation. Consequence: added methyl-group demand and metabolite load. Mitigation: counting total vitamin B3 across products.
  • Liver-stressing drugs (methotrexate, isoniazid, valproate) and heavy alcohol use: Inferred from additive hepatotoxic potential at multi-gram doses. Consequence: liver-enzyme elevation. Mitigation: ALT (alanine aminotransferase, a liver enzyme) checks when combined.
  • Anticoagulants and antiplatelets (blood-thinning drugs: warfarin, apixaban, clopidogrel, aspirin) in kidney failure: Inferred from nicotinamide-related low platelets adding to drug-induced bleeding tendency. Consequence: bleeding. Mitigation: platelet count monitoring.
  • Glucose-lowering drugs (metformin, insulin, glipizide and other sulfonylureas, which stimulate insulin release): Inferred from reduced insulin sensitivity at gram doses. Consequence: weaker glucose control. Mitigation: fasting glucose or HbA1c rechecks after starting.
  • PARP inhibitor cancer drugs (olaparib, niraparib): Inferred from nicotinamide’s own weak PARP inhibition and NAD+ supply. Consequence: unknown change in drug effect. Mitigation: discussion of use with the oncologist.

Populations who should avoid Niacinamide:

  • Active liver disease: Inferred from reversible hepatotoxicity at very high doses reported in a safety review (Knip 2000); no human data in liver disease and no source gives an enzyme threshold.
  • Hemodialysis patients outside nephrology supervision: Thrombocytopenia occurred in two dialysis trials (Shahbazian 2011; Ketteler 2023), and anemia and itching in the larger one (Ketteler 2023).
  • Pregnancy and lactation above dietary intake: The EU upper level of 900 mg/day for nicotinamide, as restated by EFSA, excludes these groups for lack of data (EFSA opinion).
  • Unsupervised use above 3 g/day: A safety review classed adult doses above 3 g/day as having toxic potential (Knip 2000).

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Tested dose ceiling: 500 mg twice daily was the skin cancer trial dose (Chen 2015); an overview of reviews found routine adverse-effect monitoring may not be indicated below 1,500 mg/day (Young 2025). Limits gastrointestinal and liver risk.
  • Split doses with meals: Two doses taken with food lower peak levels and reduce nausea and diarrhea.
  • Liver enzymes above 1.5 g/day: ALT at baseline, 8–12 weeks, then every 6–12 months; stopping if ALT exceeds three times the upper limit of normal. Prevents progression of liver injury.
  • Platelets in kidney disease: Complete blood count at baseline and 4–8 weeks if eGFR (estimated glomerular filtration rate, a kidney function measure) is below 30 mL/min/1.73 m² or on dialysis; stopping if platelets fall below 100 ×10⁹/L. Prevents thrombocytopenic bleeding.
  • Correct form: Nicotinamide (niacinamide) is the tested form, not nicotinic acid or “no-flush” inositol hexanicotinate. Prevents flushing and the higher liver risk of nicotinic acid.
  • No stacking of vitamin B3 forms: Combined nicotinamide, NR and NMN intake stays within the tested dose. Limits methyl-group demand and 2PY/4PY load.
  • Drug-level checks: Carbamazepine, or primidone and phenobarbital, levels measured 1–2 weeks after starting. Prevents toxicity or loss of seizure control.
  • Glucose check in prediabetes or diabetes: Fasting glucose or HbA1c at baseline and after 3 months. Detects reduced insulin sensitivity early.

Therapeutic Protocol

Timing, splitting, titration and cycling details below without a citation reflect common practice.

  • Skin cancer prevention (high-risk adults): 500 mg twice daily, continuously, the regimen of Damian’s Sydney group (Chen 2015); the VA cohort studied the same dose (Breglio 2025).
  • Glaucoma (investigational): 1.5 g/day for 6 weeks, then 3 g/day (Hui 2020), as in TGNT (NCT05275738); 1 g/day, then 2 g/day in normal-tension glaucoma (without raised eye pressure) (Ha 2026). Grew from Williams’ mouse work (Williams 2017).
  • Topical skin care: 5% niacinamide applied twice daily for 12 weeks (Bissett 2005).
  • Dialysis phosphate control (supervised): 250–1,500 mg/day modified-release as add-on to phosphate binders (Ketteler 2023); 500 mg/day, then 1,000 mg/day (Shahbazian 2011).
  • Upper limits: The EU upper level for nicotinamide is 900 mg/day, restated by EFSA (EFSA opinion); the US upper level of 35 mg/day covers all supplemental niacin, including nicotinamide, according to the Office of Dietary Supplements (ODS fact sheet).
  • Competing approaches: For skin cancer prevention, daily sunscreen and topical 5-fluorouracil (a chemotherapy cream) also have randomized support, according to a systematic review (Susanto 2026). For NAD+ support, NR and NMN are alternative precursors; no head-to-head clinical outcome trial exists.
  • General longevity use: No trial has tested nicotinamide for aging outcomes in healthy adults, so no evidence-based longevity dose exists.
  • Time of day: Morning and evening with meals; no time-of-day comparison exists.
  • Half-life and split dosing: Half-life is about 1.5 hours after 1 g (Stratford 1992) and 4 hours after 2 g (Stratford 1992), which supports twice-daily over once-daily dosing.
  • Genetic polymorphisms: No pharmacogenetic test guides dosing; variable NNMT methylation may explain why spinal-fluid levels rose in only some participants (Ketron 2025).
  • Sex: No sex-specific dosing exists; oral skin cancer data come mostly from men (Breglio 2025).
  • Age: Participants were mostly older adults, averaging 77 years in the VA cohort (Breglio 2025) and 74 in the Alzheimer trial (Grill 2025); no age-based dose change exists, but declining kidney function argues for staying at the tested dose.
  • Baseline biomarkers: Benefit appeared largest when started after a first skin cancer (Breglio 2025); baseline platelets, ALT and kidney function set the safety margin.
  • Pre-existing conditions: Organ transplant recipients showed no skin cancer benefit (Allen 2023); people on dialysis use lower, supervised doses.

Discontinuation & Cycling

  • Lifelong or short-term: For skin cancer prevention, use continues while risk persists, because no benefit remained after stopping (Chen 2015). Glaucoma use remains investigational; ongoing trials run two years (NCT05275738) or 27 months (NCT05405868).
  • Withdrawal effects: None reported; after stopping, the skin cancer trial showed only loss of benefit, without a rebound increase (Chen 2015).
  • Tapering: Not needed; nicotinamide can be stopped at once.
  • Cycling: No evidence supports cycling; the skin cancer effect disappears off treatment (Chen 2015).
  • Temporary stops: Pausing before surgery is not required, but platelet-related caution applies for people on dialysis.

Sourcing and Quality

  • Form: Only nicotinamide (niacinamide) matches the trials. Nicotinic acid causes flushing, and “no-flush niacin” products often contain inositol hexanicotinate instead.
  • Purity: A safety review notes that ENDIT recrystallized its nicotinamide to remove impurities and that studies using purer preparations reported better tolerance (Knip 2000).
  • Third-party testing: USP (United States Pharmacopeia) Verified, NSF (an independent certification body) Certified or ConsumerLab approval confirm content and screen for contaminants.
  • Trial suppliers: Blackmores supplies TGNT tablets (NCT05275738), and supplement maker NOW Foods collaborates on the SPRINTR transplant trial (NCT05955924), both commercial interests in the results.
  • Release form: 500 mg coated tablets were used for skin cancer (Chen 2015); modified-release nicotinamide was used in dialysis (Ketteler 2023).
  • Topical products: Trials used 5% (Bissett 2005) and 4% (Kawada 2008) niacinamide; higher concentrations lack trial support.

Practical Considerations

  • Time to effect: Actinic keratoses fell within 3 months and skin cancers over 12 months (Chen 2015); retinal electrical responses changed within 12 weeks (Hui 2020).
  • Pitfall – confusing vitamin B3 forms: Nicotinic acid, inositol hexanicotinate, NR and NMN are not interchangeable with nicotinamide in dose, side effects or evidence.
  • Pitfall – expecting lasting protection: The skin cancer benefit stops when nicotinamide stops (Chen 2015).
  • Pitfall – replacing sun protection: Nicotinamide is an add-on to sunscreen and skin checks; daily sunscreen has its own randomized support in a systematic review (Susanto 2026).
  • Regulatory status: In the US, niacin forms including nicotinamide are sold as dietary supplements (ODS fact sheet). In the EU, pure nicotinamide is authorised for foods for special medical purposes (EFSA opinion).
  • Cost and access: Inexpensive and widely available without prescription.

Interaction with Foundational Habits

  • Sleep: Direction: none documented. No trial measured sleep outcomes. Mechanistically, NAD+-dependent sirtuins help regulate the circadian clock, but no effect of nicotinamide on sleep has been shown. Taking the second dose with the evening meal avoids nighttime gastrointestinal upset.
  • Nutrition: Direction: indirect. Meat, fish, legumes, fortified grains and dietary tryptophan supply niacin far below therapeutic doses. Methyl-donor nutrients (choline, folate, betaine) supply the methyl groups used to clear excess nicotinamide (mechanistic). Heavy alcohol intake adds liver load at gram doses.
  • Exercise: Direction: potentiating (indirect). In a meta-analysis, exercise training raised muscle NAMPT, the enzyme that recycles nicotinamide toward NAD+, about 1.46-fold (Sun 2023). No data suggest nicotinamide blunts training adaptations; no timing around workouts is needed.
  • Stress management: Direction: none documented. No human data link nicotinamide to cortisol or the stress response, and no timing or technique considerations apply.

Monitoring Protocol & Defining Success

Baseline testing before starting doses above dietary intake sets safety margins and a reference for the outcomes of interest. It includes a complete blood count, liver enzymes, kidney function and fasting glucose. People using nicotinamide for skin cancer prevention have a full-skin examination documenting actinic keratoses and recent cancers, glaucoma patients use their latest visual field as baseline, and people taking carbamazepine or primidone add a drug level.

Ongoing monitoring follows this cadence: blood tests at 8–12 weeks after starting or after a dose increase, then every 6–12 months; skin examinations every 3–6 months, matching the 3-monthly checks in the skin cancer trial (Chen 2015); and visual fields at the interval set by the treating ophthalmologist. Below 1,500 mg/day, an overview of reviews found routine adverse-effect monitoring may not be indicated (Young 2025).

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Platelet count 150–450 ×10⁹/L (standard reference range) Safety check: falls with nicotinamide in kidney failure Part of a complete blood count; no fasting needed; most relevant with low eGFR or on dialysis (Ketteler 2023)
ALT 7–56 U/L (standard reference range) Safety check: liver injury at high doses Ranges vary by laboratory; usually paired with AST (aspartate aminotransferase, another liver enzyme) and bilirubin; hepatotoxicity at very high doses per a safety review (Knip 2000)
Serum creatinine with eGFR Creatinine 0.7–1.3 mg/dL (standard reference range) Safety check: reduced clearance raises exposure and platelet risk Heavy exercise and large meat meals in the 24 hours before testing can raise creatinine
Fasting glucose 70–99 mg/dL (standard reference range) Safety check: gram doses reduced insulin sensitivity 8-hour fast; paired with HbA1c in prediabetes (Greenbaum 1996)
Serum phosphate (dialysis only) 2.5–4.5 mg/dL (standard reference range) Marker expected to change: falls with nicotinamide Drawn before a dialysis session; effect faded by week 52 in the largest trial (Ketteler 2023)
Actinic keratosis and new skin cancer count No established target; track change from the individual’s own baseline count Marker expected to change: lower counts during use Full-skin dermatologist examination every 3–6 months; the skin cancer trial examined participants every 3 months (Chen 2015)
Visual field mean deviation (glaucoma only) No established target; track the rate of change from the individual’s own baseline Marker expected to change: under study Mean deviation is the average loss of visual field sensitivity versus healthy people of the same age; measured by standard automated perimetry (a computerized visual field test); primary endpoint of NAMinG (NCT05405868)

Qualitative markers:

  • Gastrointestinal comfort (nausea, loose stools, abdominal discomfort)
  • Easy bruising, nosebleeds or bleeding gums
  • New rough or scaly skin patches between examinations
  • Changes in vision, glare sensitivity or contrast
  • Itching or rash
  • Energy and general well-being

Emerging Research

  • TGNT glaucoma trial: NCT05275738 randomizes about 660 people with open-angle glaucoma to nicotinamide (1.5 g, then 3 g/day) or placebo; primary endpoint is visual field progression over two years, completion estimated December 2026. A positive result would lift glaucoma to a clinical-outcome benefit; a null result would leave only electrical signals.
  • NAMinG trial (UK): NCT05405868, phase 3, about 496 participants; primary endpoint is visual field mean deviation at 27 months, completion estimated 2027. A positive result would replicate a vision benefit across health systems; a null result would weaken the glaucoma case.
  • TAMING trial (Singapore): NCT06731582, phase 3, about 520 participants; primary endpoint is visual field mean deviation over two years. A positive result would extend evidence to Asian patients; a null result would add to the case against benefit.
  • SPRINTR transplant trial: NCT05955924, phase 3, about 396 organ transplant recipients; primary endpoint is time to first keratinocyte cancer over up to 208 weeks. NOW Foods collaborates. A positive result would challenge the earlier null transplant trial (Allen 2023); a null result would confirm no benefit after transplantation.
  • Leukemia skin cancer trial: NCT04844528, phase 2, about 86 people with chronic lymphocytic leukemia (a blood cancer that weakens immunity); primary endpoint is new nonmelanoma skin cancer at one year. A positive result would extend benefit to this immunocompromised group; a null result would match the transplant trial (Allen 2023).
  • NAD+ precursor comparison in glaucoma: NCT06991712, phase 2, about 138 participants comparing nicotinamide, NR, NMN and nicotinic acid. Its primary completion date (December 2025) has passed, it is still listed as recruiting, and no results are posted. A positive result would show which precursor works best; a null result would question the short-term glaucoma signal.
  • Completed – NEAT Alzheimer trial: NCT03061474 is completed; its published results showed no effect on the primary spinal-fluid tau endpoint (Grill 2025).
  • Ulcerative colitis trial: NCT06488625, phase 2/3, about 459 people with ulcerative colitis (chronic inflammation of the large-bowel lining); colon-targeted nicotinamide (2 or 3 g/day) versus placebo; primary endpoints are remission at 12 and 52 weeks, completion estimated 2027. A positive result would add a gut-inflammation benefit; a null result would close it.
  • Kidney protection in surgery: In a 41-patient phase 1 study, oral nicotinamide raised NAD+ metabolites and was associated with less acute kidney injury after cardiac surgery (Poyan Mehr 2018); a 20-patient pilot (NCT07739290) is planned. A positive result would add an organ-protection use; a null result would close it.
  • VITAKI septic shock trial (France): NCT04589546, phase 3, about 310 patients with septic shock; nicotinamide versus placebo, primary endpoint major adverse kidney events at 30 days. Primary completion (September 2025) has passed, status active, not recruiting, no results posted. A positive result would support kidney protection; a null result would weaken it.
  • Metabolite safety: Whether supplemental nicotinamide raises 4PY enough to matter clinically remains open, between metabolite-risk data (Ferrell 2024) and neutral user cohorts (Wheless 2025). Confirmation of risk would weaken the case for long-term high doses.

Conclusion

Niacinamide is an inexpensive, non-flushing form of vitamin B3 that the body turns into a helper molecule for energy production and genetic repair. For risk-aware adults focused on longevity, its best human support for health is for fewer new skin cancers and precancerous patches in people with heavily sun-damaged skin who have already had skin cancer. That support comes mainly from one research group, fades once the supplement is stopped, and did not hold in organ transplant recipients.

Signals for eye health in glaucoma are early and rest on electrical recordings of retinal function rather than preserved sight. Diabetes findings are mixed. Benefits for memory and slowing aging have not been shown in people; in mice, the supplement improved some health measures without lengthening life.

At the doses used in skin trials, side effects are mostly digestive and mild. Much larger doses can bring rare liver injury and a modest drop in the body’s response to insulin. People on dialysis can develop low platelet counts, itching, anemia and shingles. A breakdown product shared by all vitamin B3 forms has been tied to heart disease in population studies, though records of supplement users show no extra events.

Outside skin cancer the evidence is thin, and parts come from parties with commercial interests: a cosmetics maker behind the skin-appearance research, a drug maker funding the main dialysis trial, and supplement companies supporting ongoing trials. On current evidence, niacinamide is a targeted skin-cancer measure for high-risk skin rather than an established longevity agent.

Top - Benefits - Risks - Protocol